| Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 A Goldhirsch, EP Winer, AS Coates, RD Gelber, M Piccart-Gebhart, ... Annals of oncology 24 (9), 2206-2223, 2013 | 4309 | 2013 |
| KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer A Lievre, JB Bachet, D Le Corre, V Boige, B Landi, JF Emile, JF Côté, ... Cancer research 66 (8), 3992-3995, 2006 | 2798 | 2006 |
| The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014 R Salgado, C Denkert, S Demaria, N Sirtaine, F Klauschen, G Pruneri, ... Annals of oncology 26 (2), 259-271, 2015 | 2653 | 2015 |
| Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective … W De Roock, B Claes, D Bernasconi, J De Schutter, B Biesmans, ... The lancet oncology 11 (8), 753-762, 2010 | 2567 | 2010 |
| Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up F Cardoso, S Kyriakides, S Ohno, F Penault-Llorca, P Poortmans, ... Annals of oncology 30 (8), 1194-1220, 2019 | 2239 | 2019 |
| Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group M Dowsett, TO Nielsen, R A’Hern, J Bartlett, RC Coombes, J Cuzick, ... Journal of the National cancer Institute 103 (22), 1656-1664, 2011 | 2026 | 2011 |
| Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up E Senkus, S Kyriakides, S Ohno, F Penault-Llorca, P Poortmans, ... Annals of oncology 26, v8-v30, 2015 | 2018 | 2015 |
| KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab A Lievre, JB Bachet, V Boige, A Cayre, D Le Corre, E Buc, M Ychou, ... Journal of clinical oncology 26 (3), 374-379, 2008 | 1952 | 2008 |
| 4th ESO–ESMO international consensus guidelines for advanced breast cancer (ABC 4) F Cardoso, E Senkus, A Costa, E Papadopoulos, M Aapro, F André, ... Annals of Oncology 29 (8), 1634-1657, 2018 | 1224 | 2018 |
| 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) F Cardoso, S Paluch-Shimon, E Senkus, G Curigliano, MS Aapro, F André, ... Annals of Oncology 31 (12), 1623-1649, 2020 | 1023 | 2020 |
| Cancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy A Sistigu, T Yamazaki, E Vacchelli, K Chaba, DP Enot, J Adam, I Vitale, ... Nature medicine 20 (11), 1301-1309, 2014 | 1017 | 2014 |
| Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT) F Barlesi, J Mazieres, JP Merlio, D Debieuvre, J Mosser, H Lena, ... The Lancet 387 (10026), 1415-1426, 2016 | 932 | 2016 |
| 3rd ESO–ESMO international consensus guidelines for advanced breast cancer (ABC 3) F Cardoso, A Costa, E Senkus, M Aapro, F André, CH Barrios, J Bergh, ... The Breast 31, 244-259, 2017 | 874 | 2017 |
| Analysis of PTEN, BRAF, and EGFR Status in Determining Benefit From Cetuximab Therapy in Wild-Type KRAS Metastatic Colon Cancer P Laurent-Puig, A Cayre, G Manceau, E Buc, JB Bachet, T Lecomte, ... Journal of clinical oncology 27 (35), 5924-5930, 2009 | 854 | 2009 |
| ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2) F Cardoso, A Costa, L Norton, E Senkus, M Aapro, F Andre, CH Barrios, ... The Breast 23 (5), 489-502, 2014 | 836 | 2014 |
| Prediction of BRCA1 Status in Patients with Breast Cancer Using Estrogen Receptor and Basal Phenotype SR Lakhani, JS Reis-Filho, L Fulford, F Penault-Llorca, M van der Vijver, ... Clinical cancer research 11 (14), 5175-5180, 2005 | 827 | 2005 |
| Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple … EA Mittendorf, H Zhang, CH Barrios, S Saji, KH Jung, R Hegg, A Koehler, ... The Lancet 396 (10257), 1090-1100, 2020 | 782 | 2020 |
| Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up E Senkus, S Kyriakides, F Penault-Llorca, P Poortmans, A Thompson, ... Annals of oncology 24, vi7-vi23, 2013 | 696 | 2013 |
| Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism? L Arnould, M Gelly, F Penault-Llorca, L Benoit, F Bonnetain, C Migeon, ... British journal of cancer 94 (2), 259-267, 2006 | 685 | 2006 |
| Assessing tumor-infiltrating lymphocytes in solid tumors: a practical review for pathologists and proposal for a standardized method from the International Immuno-Oncology … S Hendry, R Salgado, T Gevaert, PA Russell, T John, B Thapa, M Christie, ... Advances in anatomic pathology 24 (6), 311-335, 2017 | 676 | 2017 |
